Autres langues Organovo Holdings, Inc.

Actions

ONVO

US68620A2033

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 01/05/2024			Varia. 5j.	Varia. 1 janv.
0,9311 ^USD	-12,98%		-6,89%	-16,12%

15/04	Le médicament d'Organovo contre la stéatose hépatique atteint son objectif principal lors d'une étude de mi-parcours	RE
15/04	Organovo Holdings, Inc. Annonce des résultats positifs de l'étude de phase 2 sur le FXR314 dans la stéatohépatite associée à un dysfonctionnement métabolique, montrant à la fois une réduction de la teneur en graisse du foie et une sécurité et une tolérabilité élevées par rapport au placebo.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	16/04
Organovo's fatty liver disease drug meets main goal in mid-stage study	15/04
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	15/04
Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	15/04
Organovo: Fiscal Q3 Earnings Snapshot	08/02
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress	25/01
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings	25/01
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress	09/01
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results	06/12
Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results	06/12
Organovo: Fiscal Q2 Earnings Snapshot	10/11
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11
Organovo Highlights FXR314 Combination Therapy Potential and Plan	08/11
Organovo Holdings, Inc. Highlights FXR314 Combination Therapy Potential and Plan	08/11
Organovo : Submission of Matters to a Vote of Security Holders - Form 8-K	03/11
Organovo to Participate in the H.C. Wainwright Global Investment Conference	08/09/23
Organovo : Change in Certifying Accountants - Form 8-K	05/09/23
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data	23/08/23
Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data	23/08/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Organovo Holdings, Inc.

Actions

ONVO

US68620A2033

Autres langues

Filtres